Ji-Li Chen, Amina Dawoodji, Andrea Tarlton, Sacha Gnjatic, Abdelouahid Tajar, Ioannis Karydis, Judy Browning, Sarah Pratap, Christian Verfaille, Ralph R Venhaus, Linda Pan, Douglas G Altman, Jonathan S Cebon, Lloyd L Old, Paul Nathan, Christian Ottensmeier, Mark Middleton, Vincenzo Cerundolo
Vaccination strategies based on repeated injections of NY-ESO-1 protein formulated in ISCOMATRIX particles (NY-ESO-1 ISCOMATRIX) have shown to elicit combined NY-ESO-1 specific antibody and T cell responses. However, it remains unclear whether heterologous prime-boost strategies based on the combination with NY-ESO-1 ISCOMATRIX with different NY-ESO-1 boosting reagents could be used to increase NY-ESO-1 CD8(+) or CD4(+) T cell responses. To address this question, we carried out a randomized clinical trial in 39 high-risk, resected melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX, and then boosted with repeated injections of either recombinant fowlpox virus encoding full length NY-ESO-1 (rF-NY-ESO-1) (Arm A) or NY-ESO-1 ISCOMATRIX alone (Arm B)...
March 15, 2015: International Journal of Cancer. Journal International du Cancer